https://scholars.lib.ntu.edu.tw/handle/123456789/627191
標題: | ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240 | 作者: | Vogel, Arndt Merle, Philippe Verslype, Chris Finn, Richard S Zhu, Andrew X ANN-LII CHENG Chan, Stephen Lam Yau, Thomas Ryoo, Baek-Yeol Knox, Jennifer Daniele, Bruno Qin, Shukui Wei, Ziwen Miteva, Yanna Malhotra, Usha Siegel, Abby B Kudo, Masatoshi |
關鍵字: | PD-1 inhibitor; albumin-bilirubin score; hepatocellular carcinoma; liver function; pembrolizumab | 公開日期: | 2021 | 出版社: | SAGE PUBLICATIONS LTD | 卷: | 13 | 來源出版物: | Therapeutic advances in medical oncology | 摘要: | This post hoc analysis evaluated albumin/bilirubin (ALBI) score, an objective measure of liver function, in patients receiving pembrolizumab plus best supportive care (BSC) compared with placebo plus BSC in the KEYNOTE-240 study. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/627191 | ISSN: | 1758-8340 | DOI: | 10.1177/17588359211039928 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。